Search
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigationalTocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersLevocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigationalLevocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine. Levocetirizine w...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAmisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigationalAmisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and ...
Categories: P-glycoprotein substratesElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigationalElacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. It re...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLestaurtinib
go.drugbank.com/drugs/DB06469InvestigationalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsMitemcinal
go.drugbank.com/drugs/DB06587InvestigationalMitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAgomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potent...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Synonyms: p-AminopyridineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesVicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was develop...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates